Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
432.27
-7.18 (-1.63%)
Sep 12, 2025, 4:00 PM EDT - Market closed
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $474.67, which forecasts a 9.81% increase in the stock price over the next year. The lowest target is $350 and the highest is $554.
Price Target: $474.67 (+9.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 5 | 6 | 7 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $428 → $526 | Strong Buy | Maintains | $428 → $526 | +21.68% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $500 | Strong Buy | Initiates | $500 | +15.67% | Sep 4, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $390 → $554 | Strong Buy | Maintains | $390 → $554 | +28.16% | Aug 26, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $483 → $485 | Buy | Maintains | $483 → $485 | +12.20% | Aug 20, 2025 |
| UBS | UBS | Strong Buy Maintains $458 → $523 | Strong Buy | Maintains | $458 → $523 | +20.99% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
890.07M
from 180.13M
Increased by 394.12%
Revenue Next Year
1.40B
from 890.07M
Increased by 57.74%
EPS This Year
-10.67
from -21.90
EPS Next Year
1.99
from -10.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 953.3M | 1.8B | |||
| Avg | 890.1M | 1.4B | |||
| Low | 816.8M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 429.2% | 97.7% | |||
| Avg | 394.1% | 57.7% | |||
| Low | 353.4% | 23.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.95 | 13.39 | |||
| Avg | -10.67 | 1.99 | |||
| Low | -14.95 | -6.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.